Sustainability kudos EcoVadis Bronze Medal awards in 2024 and 2026 highlight a recognized commitment to sustainability which can be leveraged to align with potential biopharma partners prioritizing responsible supply chains and ESG-focused procurement.

Strategic partnerships Recent collaborations and integrations with CCRM Nordic and Karolinska Institutet, plus a philanthropy-aligned SCN2A foundation partnership, indicate a track record of co-development and large-scale capabilities that can be marketed to biotech firms seeking translational and advanced neuronal model expertise.

Expanded service scope Launch of Neurotoxicity Testing Services and established modules in Neuroinflammation, Neuropathies, Neurodegeneration, and Neuroplasticity demonstrate a broader capability set for early safety assessment and target discovery, appealing to teams needing integrated neurobiology workflows.

Geographic growth Appointment of a Head of Japan Business Development signals intent to scale in Asia-Pacific, offering channel and regional sales opportunities for localized support, regulatory considerations, and proximity to key Japanese and regional life sciences customers.

Financial footprint Sub-$1M revenue with $14M in funding suggests a lean, high-potential partner with room for scaled collaborations, milestone-driven engagements, and co-funded research programs attractive to early-stage biotech customers seeking cost-efficient in vitro neurobiology solutions.